Chitosan and chitosan nanoparticles as adjuvant in local Rift Valley Fever inactivated vaccine

El-Sissi, Ashgan F.; Mohamed, Farida H.; Danial, Nadia M.H.; Gaballah, Ali Q.; Ali, Korany A.

doi:10.1007/s13205-020-2076-y

Cited by 28 publications

(24 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They also utilized other combinations of RVFV-based vaccines such as RVFV-chitosan (RVFV-CS), RVFV-Alum, and adjuvant-free RVFV. In vivo vaccination of Swiss albino mice validated the safety and stimulation of innate and adaptive immunity by upregulating IL-2, IFN-γ and IL-4 in RVFV-CS and RVFV-CNP treatment groups, with later demonstrating superior efficacy compared to other groups [ 29 ]. Biodegradable nanoparticles are advantageous as they can mimic the priming and boosting effect by modified release and potential for single-shot vaccines reducing the cost of vaccination.…”

Section: Nanotechnology-based Vaccines Vaccine Adjuvants and Delivery Systemsmentioning

confidence: 99%

An Overview of Nanocarrier-Based Adjuvants for Vaccine Delivery

et al. 2021

View full text Add to dashboard Cite

The development of vaccines is one of the most significant medical accomplishments which has helped to eradicate a large number of diseases. It has undergone an evolutionary process from live attenuated pathogen vaccine to killed whole organisms or inactivated toxins (toxoids), each of them having its own advantages and disadvantages. The crucial parameters in vaccination are the generation of memory response and protection against infection, while an important aspect is the effective delivery of antigen in an intelligent manner to evoke a robust immune response. In this regard, nanotechnology is greatly contributing to developing efficient vaccine adjuvants and delivery systems. These can protect the encapsulated antigen from the host’s in-vivo environment and releasing it in a sustained manner to induce a long-lasting immunostimulatory effect. In view of this, the present review article summarizes nanoscale-based adjuvants and delivery vehicles such as viral vectors, virus-like particles and virosomes; non-viral vectors namely nanoemulsions, lipid nanocarriers, biodegradable and non-degradable nanoparticles, calcium phosphate nanoparticles, colloidally stable nanoparticles, proteosomes; and pattern recognition receptors covering c-type lectin receptors and toll-like receptors.

show abstract

Section: Nanotechnology-based Vaccines Vaccine Adjuvants and Delivery Systemsmentioning

confidence: 99%

An Overview of Nanocarrier-Based Adjuvants for Vaccine Delivery

et al. 2021

View full text Add to dashboard Cite

show abstract

“…IL-10 stimulated cytotoxicity of CD8 + T cells and IFN-γ expression 33 . IL-4 promoted humoral immunity and IFN-γ promoted cell-mediated immunity 34 . LTB, LTB26 and LTB57 significantly upregulated the expression of IFN-γ and TNF-α compared with VP8 alone treatment, but there were no differentiation among LTB, LTB26 and LTB57 (Fig.…”

Section: Discussionmentioning

confidence: 99%

SARS-COV-2 RBD Oral Vaccine Boosted by Mucosal Immune Adjuvant LTB26 via DCs and B Cells Activation in Mice

Shi

Wang

et al. 2020

Preprint

View full text Add to dashboard Cite

Heat-labile enterotoxin B subunit (LTB) of Escherichia coli is a potential mucosal immune adjuvant for its safety. However, the weaker adjuvant activity fails to meet the clinical requirement. Here, one of LTB mutant numbered LTB26 is constructed with enhanced mucosal immune adjuvanticity than that of LTB wild type (LTB). The transcriptome analysis data suggest that LTB26 enhances mucosal immune adjuvanticity via increased expression of BCR and MHC II + molecular. Furthermore, LTB26 can promote both Th1 and Th2 cell mediated immunity via upregulated expression of IL-4 and IFN-γ. Flow cytometry analysis confirms that LTB26 significantly upregulates the activity of antigen presenting cells (DCs and mature macrophage) compared with LTB and LTB57 mutant. The result demonstrates that LTB26 is a potent mucosal immune adjuvant meeting clinical requirement. The GM1 ganglioside (GM1) binding activity of LTB57 is higher than that of LTB26; instead, the immune adjuvanticity of LTB57 is lower than that of LTB26. The 3 result highlights that the immune adjuvanticity of LTB and its mutant are not positively associated with GM1 affinity, which upends decades understanding of the relationship of LTB adjuvanticity and GM1-binding affinity.

show abstract

“…Moreover, the difficulty in administration and development of slower immunological response based on time-taking chemical interactions at cellular levels were major issues with DNA vaccines. Chitosan nanoparticles have the intrinsic ability to adhere with mucosal layers of host; this cationic feature makes them efficient cargo for antigen delivery [ 16 ]. Similarly, by virtue of ionic cross-linkages, the use of biopolymers could improvise endocytosis by host cells.…”

Section: The Biochemistry Of Nano-vaccinesmentioning

confidence: 99%

“…A complementary approach has shown reasonable immune protection against dengue virus challenge [ 35 ]. Other viral diseases that have been shown to be prevented by nano-vaccines include avian influenza (H3N2), respiratory syncytial viruses, parainfluenza virus, Rift Valley Fever Virus and most importantly, the corona viruses (MERS, SARS) [ 16 , 36 ].…”

Section: Nano-vaccines Against Pathogensmentioning

confidence: 99%